News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

1606 Corp announces cutting-edge AI-driven CHATCBDW is live and in operation

1606 Corp.

1606 Corp CEO Greg Lambrecht joined Steve Darling from Proactive to share news the company has officially unveiled its cutting-edge AI chatbot, ChatCBDW, which represents a significant advancement in the world of CBD products and customer engagement. Lambrecht explained that ChatCBDW has undergone key designs and rigorous testing before being launched and is now live and operational. This innovative chatbot offers a wide range of user-centric features that go beyond the ordinary. One of its standout attributes is its capability to respond to user inquiries and provide comprehensive education on all aspects of CBD. However, ChatCBDW doesn't stop there. It takes personalization to the next level by offering tailored product recommendations to users and engaging in conversations that closely mimic human interaction. This level of innovation empowers customers to make well-informed choices, explore a diverse array of CBD products, and promises an unparalleled shopping experience within the CBD industry. The seamless integration of ChatCBDW with Microsoft Azure is a key component of its capabilities. Microsoft Azure is renowned for its scalability, unwavering reliability, and cutting-edge AI functionalities. This integration ensures that ChatCBDW can operate impeccably, even during periods of peak demand, delivering users a consistently responsive and seamless experience throughout their interaction with the chatbot. The company has also announced that Cool Blue Distribution is now a North American licensed reseller of ChatCBDW and is set to engage its network of over 800 CBD retailers immediately. The first direct-to-merchant marketing campaign is scheduled to begin by mid-November 2023, with the goal of generating notable revenue before January 1, 2024. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

October 31, 2023 03:16 PM Eastern Daylight Time

Video
Article thumbnail News Release

Stay Ahead of Cough, Cold and Flu Season

YourUpdateTV

As the colder months approach, millions of people across the nation are gearing up for the inevitable cough, cold and flu season. Recently, Emergency Room Physician, Dr. Darria Long, conducted a satellite media tour to share tips and advice on how to stay healthy and prepared. A video accompanying this announcement is available at: https://youtu.be/5yVw5AWHbXw As the colder months approach, millions of people across the nation are gearing up for the inevitable cold and flu season. The cough, cold and flu season is marked by a significant increase in the spread of respiratory viruses, which can lead to a surge in illnesses and medical visits. Advanced preparation provides an opportunity to ensure that necessary supplies, medications, and remedies are readily available. Having essential items, like Mucinex 12H, on hand before symptoms strike can make a significant difference. Mucinex 12-Hour relieves chest congestion and thins and loosens mucus. It is clinically proven to last up to 12 hours and provide relief for your chest congestion and make coughs more productive. One dose of Mucinex 12-Hour lasts 3 times longer than other 4-HR medicines helping individuals manage discomfort effectively and get back to their daily activities sooner. Always use over-the-counter products as directed. If symptoms persist, you should contact your healthcare professional and get checked out if deemed necessary. Taking better care of ourselves during the cough, cold and flu season is paramount to staying healthy and minimizing the risk of falling ill. Key preventative measures like washing your hands often, covering your nose and mouth with a tissue when you cough or sneeze, and sneezing into your elbow if you don’t have a tissue are extremely effective at preventing the spread of germs. Additionally, maintaining a healthy lifestyle is crucial. Adequate sleep, a balanced diet rich in fruits and vegetables, regular physical activity, and managing stress contribute to a strong immune system. Staying hydrated by drinking plenty of fluids, particularly water and herbal teas, can also help keep our respiratory tract moist and better able to fend off viruses. For more information on how to take care of yourself this cold and flu season, visit Mucinex.com. You can stop by Walmart, Target, your local pharmacy or food retailer to buy Mucinex now ahead of this cough and cold season. BIO: Dr. Darria Long, MD Dr. Darria Long leverages the best of science, to make our lives healthier, better… and easier. By combining her life’s work as an Emergency Room physician and being a mom of two – Dr. Darria has become the nation’s ‘making life better for women’ doctor by helping individuals pave ways to stay present and remain healthy during times of constant distractions and high stress. With a website devoted to distilling health headlines and creating a thriving lifestyle, Dr. Darria shares simple, evidence-based (from western, eastern, and integrative medicine) advice on physical and mental wellness, and the health guidance you’d expect and trust from a close friend. A favored national TV contributor and national bestselling author of Mom Hacks, Dr. Darria is also a TED speaker “How to triage your life like an ER doctor,” and Clinical Assistant Professor at the University of Tennessee. She received her training in emergency medicine at Yale School of Medicine and her MBA from Harvard Business School. A featured regular on CNN, Headline News, NBC, Interview Healthline, Hallmark, Lifetime, Dr. Oz, Thrive Global, Atlanta Small Business Network, Parenting for the future, and many others. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

October 31, 2023 01:04 PM Eastern Daylight Time

Video
Article thumbnail News Release

PathAI Announces Research Presentations at the Society for Immunotherapy of Cancer’s 38th Annual Meeting

PathAI

PathAI, a leading technology company which combines AI-powered pathology solutions with end-to-end central pathology and histology services, today announced it will present research underscoring the efficacy of PathExplore’s human interpretable features (HIFs) through three poster presentations at the Society for Immunotherapy of Cancer’s 38 th Annual Meeting on November 1-5 in San Diego, CA. The posters showcase how PathExplore provides high-resolution characterization of the tumor microenvironment (TME) through a standardized panel of HIFs derived from H&E whole slide images across multiple cancer types. Additionally, Incendia Therapeutics will present two posters reporting results that were generated utilizing PathExplore. “Building upon past publications and presentations, we continue to see the utility for histological features of the tumor microenvironment to further our understanding of disease biology, patient prognosis, and therapeutic response, which ultimately may lead to the discovery and implementation of novel biomarkers to advance precision medicine,” explained Mike Montalto, Ph.D., Chief Scientific Officer, PathAI. All three posters demonstrate the correlation between specific HIFs and established molecular measurements of the TME (e.g., gene expression profiles of specific cell populations), as well as specific HIFs and complex molecular signatures (e.g., immune phenotypes) which could better aid in the identification of patients eligible for targeted therapies, or result in the identification of new histology-based biomarkers. Quantifying the effect of microsatellite instability and mismatch repair deficiency on the tumor microenvironment (Poster 73) In this research, PathAI investigated the potential to predict and compare microsatellite stability and mismatch repair subtypes in colorectal and endometrial cancers utilizing PathExplore HIFs. The findings suggest MSS/dMMR tumors may warrant consideration for immunotherapy due to their TME’s similarity to microsatellite instability-high (MSI-H) and tumor mutation burden-high (TMB-H) solid tumors and AI-powered analysis of H&E WSI presents a more accessible and scalable method than current dMMR testing options. This poster will be presented by Judy Chen and Shima Nofallah on Friday, November 3 rd. Poster hall hours are 9 a.m. to 7 p.m. PT. Quantification of tumor infiltrating lymphocytes (TILs) from pathology slides reflects molecular immune phenotypes (Poster 122) In this research, PathAI deployed its PathExplore products on H&E WSI across eight cancer indications to extract HIFs quantifying the TME, including features that represent TIL fractions, densities, and distributions. Analysis revealed statistically significant correlations between TIL-associated HIFs with gene expression of known lymphocyte markers, as well as immune signature scores such as lymphocyte infiltration. These results show the predictive power that TIL-associated HIFs have for identifying immune phenotypes, as well as a promising direction for the discovery of histology-based immune biomarkers. This poster will be presented by Judy Shen on Saturday, November 4 th. Poster hall hours are 9 a.m. to 8:30 p.m. PT. Deep learning models identify key tumor microenvironment features associated with genetic signatures of UV metagenesis and alkylating agent treatment in melanoma (Poster 110) In this research, PathAI used PathExplore HIFs to investigate the association between TME features and mutational signatures indicative of UV mutagenesis, as well as alkylating agents-induced mutations. The results suggest that quantifying a tumor’s tissue and cellular composition can reveal meaningful information regarding the underlying mutation-driven or treatment-induced changes in the TME, which may have implications for therapy selection. This poster will be presented by Shima Nofallah on Saturday, November 4 th. Poster hall hours are 9 a.m. to 8:30 p.m. PT. Incendia Therapeutics (formerly known as Parthenon Therapeutics) posters In addition to the posters above, Incendia Therapeutics will present two posters on Friday, November 3 rd reporting results that were generated utilizing PathExplore. One poster (Poster 1287) compares PathExplore HIFs to mIF features and concluded that "TME models are a robust tool to distinguish tissue and cell features from H&E slides, comparable to mlF image analysis, but requiring less effort, time, and expense." In the second (Poster 1497), Incendia Therapeutics leveraged HIFs quantifying lymphocyte densities across cancer epithelium, cancer stroma, and the epithelial-stromal interface (ESI) to characterize barriers to lymphocyte entry into the cancer epithelium across immune phenotypes. More information on these posters can be found at https://www.incendiatx.com ​​Please visit the PathAI booth, 615, to learn more and meet the team, or email us at bd@pathai.com. About PathAI PathAI is the only AI-focused technology company to provide comprehensive precision pathology solutions from wet lab services to algorithm deployment for clinical trials and laboratory use. Rigorously trained and validated with data from more than 15 million annotations, its AI-powered models can be leveraged to optimize the analysis of pathology samples to improve efficiency and accuracy of pathology interpretation, as well as to better gauge therapeutic efficacy and accelerate drug development for complex diseases. PathAI, which is headquartered in Boston, MA, and operates a CAP/CLIA-certified laboratory in Memphis, TN, is proud to have a team of 600+ innovative thinkers from around the globe. For more information, please visit www.pathai.com. Contact Details SVM Public Relations and Marketing Communications Maggie Naples +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

October 31, 2023 10:00 AM Eastern Daylight Time

Article thumbnail News Release

Evgen Pharma "delighted" with cash position after promising first half

Evgen Pharma PLC

Evgen Pharma PLC (AIM:EVG) CEO Dr Huw Jones and new CFO Toni Hanninen speak to Thomas Warner from Proactive after the clinical stage drug development company announced its interim results for the six months to 31 September 2023. Dr Jones gives an overview of how Evgen has been performing on the operational side, highlighting clinical progress, the successful receipt of some new grant funding as well as changes to the board and to the executive team with the hiring of Toni Hanninen in late summer. Hanninen gives an overview of how Evgen performed financial during the reporting period, noting that there were no nasty surprises during the six months and that the company's cash runway of £3.7mln currently runs to the end of 2024. He goes on to say that he is "very very delighted" with the length of the runway given the financial challenges many of Evgen's peers are currently facing. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

October 31, 2023 06:43 AM Eastern Daylight Time

Video
Article thumbnail News Release

Marizyme Inc CEO releases corporate update including details of key progress on DuraGraft

Marizyme Inc

Marizyme Inc CEO David Barthel joined Steve Darling from Proactive to provide an exciting update on the remarkable progress that the company has achieved in recent months. Among the standout developments is the approval received from the US Food and Drug Administration for its groundbreaking product, DuraGraft. DuraGraft is a first-in-class vascular conduit solution that has received FDA clearance, marking a significant milestone for Marizyme. This innovative product is specifically indicated for use in adult patients undergoing Coronary Artery Bypass Grafting (CABG) surgeries. Its primary purpose is to facilitate the flushing and storage of saphenous vein grafts employed in CABG procedures, offering a cutting-edge solution to enhance patient outcomes in cardiac surgery. One notable aspect of Marizyme's progress is the growing acceptance of DuraGraft in both Europe and Asia. The company has achieved impressive sales figures, with a total of 1,131 DuraGraft kits shipped so far this year. This is a remarkable increase compared to the 485 DuraGraft kits shipped in the previous year, underscoring the product's traction and demand in the international market. In summary, Marizyme, under the leadership of CEO David Barthel, is making significant strides in the medical industry. The FDA approval of DuraGraft and its increasing adoption in international markets signify the company's commitment to advancing medical technologies that improve patient outcomes. As Marizyme continues to expand its reach and forge new partnerships, it is poised for continued growth and success in the years ahead. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

October 30, 2023 03:23 PM Eastern Daylight Time

Video
Article thumbnail News Release

BioHarvest Sciences closes first tranche of financing bringing in C$11.78M to Treasury

BioHarvest Sciences Inc.

BioHarvest Sciences CEO Ilan Sobel joined Steve Darling from Proactive to share some exciting developments. The company has achieved a major milestone by successfully closing the first tranche of its financing, raising nearly C$12 million, even in the face of challenging market conditions. This accomplishment underscores the significant investor confidence in BioHarvest's strategic vision and the strength of its management team. The capital raised through this financing round will play a pivotal role in advancing several key initiatives within BioHarvest Sciences. One of the notable areas of focus is new product development and expansion. BioHarvest has ambitious plans to expand its product range, moving from a single SKU to ten SKUs spanning five different categories. Leveraging its advanced scientific capabilities, proven efficacy, and exceptional taste, the company is poised to make a significant impact in these markets. The eagerly awaited flagship product, a revolutionary coffee offering, is slated to disrupt the market starting in December. Geographical expansion is another crucial aspect of BioHarvest's growth strategy. With recent approval from Health Canada, the company is gearing up to enter the Canadian market, further extending its global footprint. Additionally, BioHarvest is accelerating clinical trials across various domains, positioning itself for substantial growth over the next 12 to 24 months. These clinical trials will not only underscore the efficacy of their products but also enhance their credibility and market presence. Despite the challenges posed by the current market conditions, BioHarvest remains unwavering in its commitment to the safety of its employees and the consistent delivery of high-quality products. The company's focus for the remainder of 2023 includes robust marketing initiatives and the highly anticipated launch of its innovative coffee product, aimed at revitalizing the stagnant decaffeinated coffee market. Contact Details Proactive Investors Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

October 30, 2023 03:18 PM Eastern Daylight Time

Video
Article thumbnail News Release

1606 Corp announces cutting-edge AI-driven ChatCBDW will launch on Tuesday

1606 Corp.

1606 Corp CEO Greg Lambrecht joined Steve Darling from Proactive to unveil some thrilling news: the impending launch of its cutting-edge AI chatbot, ChatCBDW. With ChatCBDW currently undergoing final testing phases, the countdown to its official launch is well underway. Lambrecht eagerly shared with Proactive the multifaceted capabilities that ChatCBDW is poised to bring to its users. This AI chatbot has been meticulously designed to offer a diverse range of user-centric features that go beyond the ordinary. Among its standout attributes are its ability to respond to user queries and provide comprehensive education on all aspects of CBD. But ChatCBDW doesn't stop there; it takes personalization to the next level by offering tailored product recommendations to users and engaging in conversations that closely mimic human interaction. This innovation empowers customers to make well-informed choices, explore a wide array of CBD products, and promises an unparalleled shopping experience in the CBD space. At the core of ChatCBDW's prowess is its seamless integration with Microsoft Azure, a platform renowned for its scalability, unwavering reliability, and cutting-edge AI functionalities. This integration ensures that ChatCBDW can operate impeccably, even during peak demand periods, guaranteeing users a consistently responsive and seamless experience throughout their interaction with the chatbot. Notably, 1606 Corp proudly retains 100% ownership of ChatCBDW's intellectual property, demonstrating its commitment to maintaining control over this groundbreaking technology. This ownership provides the company with the flexibility to continually enhance and adapt ChatCBDW to meet the ever-evolving needs of its users and partners across various industries. It signifies 1606 Corp's dedication to staying at the forefront of innovation in the field of AI-driven customer engagement and CBD product discovery. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

October 30, 2023 02:16 PM Eastern Daylight Time

Video
Article thumbnail News Release

BioVie CEO reveals stunning results in Alzheimer's and Parkinson's drug trial

BioVie Inc

BioVie Inc CEO Cuong Do joined Steve Darling from Proactive to share news the company will be presenting its blinded data on cognitive, biomarker, and imaging findings from the recently completed Phase 3 clinical trial of NE3107 in the treatment of mild to moderate Alzheimer’s Disease. The presentation will be presented at the upcoming 16th Clinical Trials on Alzheimer's Disease in Boston. Do told Proactive the company has monitored blinded data as they become available throughout the trial to assess patient safety and support timely data entry into the official statistical analysis database. Interim blinded data was previously presented at other scientific congresses to provide a glimpse of the characteristics of the enrolled subjects at the start of the trial. The most surprising revelation was the reduction in amyloid burden. NE3107, designed to block TNF alpha, demonstrated a substantial reduction in amyloid buildup within just six months of treatment. More than a third of initially amyloid-positive patients became amyloid-negative, a highly unexpected outcome. Contact Details Proactive USA +1 347-449-0879 na-editorial@proactiveinvestors.com

October 30, 2023 01:00 PM Eastern Daylight Time

Video
Article thumbnail News Release

Majority of medical and nursing students planning careers outside patient care as fears of burnout and staff shortages leave them worried about the future

Elsevier

Elsevier Health’s first global “Clinician of the Future 2023: Education Edition” highlights students’ deep concerns about balancing their commitment to patient care with their own well-being. The report also identifies key insights into students’ excitement and fears towards technology and AI in healthcare education Today, Elsevier Health, a global leader in evidence-based clinical practice content, research publishing and information analytics, releases its Clinician of the Future 2023: Education Edition, providing unparalleled insights into the experiences of medical and nursing students and the consequences for the NHS and educators in the UK. The report reveals how the challenges of being a frontline health professional today are impacting the longer-term career decisions of students, highlighting increasingly challenging times ahead for an already overburdened healthcare system. Although almost 9 out of 10 medical and nursing students in the UK feel devoted to improving patients’ lives, findings reveal that 58% already see their current studies as a steppingstone towards a broader career in healthcare that will not involve directly caring for patients. The Clinician of the Future 2023: Education Edition presents a worrying snapshot of the pressures that medical and nursing students feel today alongside the impending alarm they have for life in clinical practice: 20% of medical and nursing students in the UK are considering quitting their undergraduate studies 57% of medical and nursing students in the UK report they are worried about their mental well-being 64% of medical and nursing students in the UK believe they will suffer from clinician burnout 75% of medical and nursing students in the UK are concerned about healthcare staff shortages and the impact this would have on them in their future role Anjola Awe, a third-year medical student at King’s College London, said: “I have always known that I wanted to be a doctor; I’ve dedicated my life to getting to this stage. Honestly, the findings and themes in the report are not at all surprising to me or my peers; we know only too well the reality of what being a frontline healthcare professional means today. We need to be vocal about the pressure we are under, the state of our mental health, and the volume of our academic workload.” As of June this year, there were more than 125,000 vacancies in secondary care in England, and over 10% of all nursing posts remain unfilled. 1 Despite the NHS treating more patients than before the pandemic, the waiting list for NHS treatment currently stands at a record 7.75 million. 2 Against this backdrop, it is unsurprising that medical and nursing students in the UK are concerned about the challenges they will face in the future. Dr Philip Xiu, a general practitioner and educational lead who supports medical students and junior doctors in Leeds, West Yorkshire, said: “As an educator, I see daily how vital it is we address students’ well-being concerns. Doubling enrolment won’t resolve looming workforce shortages if issues impeding student wellness go unresolved. We must equip them with critical thinking to aid sound clinical decisions, and partnership skills to involve patients meaningfully in care. By listening and responding to students’ needs, we can graduate resilient, empowered clinicians ready to elevate healthcare.” The Clinician of the Future 2023: Education Edition also identifies key insights into both the excitement and reservation towards technology and generative AI student curriculum. In the UK, 53% of medical and nursing students say they are excited at the potential of AI; however, 54% report they are worried about its use to support education. Furthermore, 74% admit to feeling overwhelmed by the amount of information they are expected to retain, with 44% now using generative AI, such as ChatGPT and Bard. Jan Herzhoff, President of Elsevier Health, said: “It’s clear that healthcare across the globe is facing unprecedented pressures, and that the next generation of medical and nursing students are anxious about their future. Whether through the use of technology or engaging learning resources, we must support students with new and innovative approaches to enable them to achieve their potential. However, the issues raised in this report can’t be tackled in isolation; it is essential that the whole healthcare community comes together to ensure a sustainable pipeline of healthcare professionals.” The Clinician of the Future 2023: Education Edition is the third edition published as part of Elsevier Health’s Clinician of the Future program, serving as the global health ecosystem’s leading pulse on the changes and challenges facing the doctors and nurses of today and tomorrow. For the full Clinician of the Future 2023: Education Edition, which includes robust data on global student attitudes toward health education, the future of healthcare, as well as the perspectives of instructors and more, click here. ### References: The British Medical Association. NHS medical staffing data analysis, The British Medical Association. Available at: https://www.bma.org.uk/advice-and-support/nhs-delivery-and-workforce/workforce/nhs-medical-staffing-data-analysis (Accessed: 18 October 2023). The British Medical Association. NHS backlog data analysis, The British Medical Association. Available at: https://www.bma.org.uk/advice-and-support/nhs-delivery-and-workforce/pressures/nhs-backlog-data-analysis (Accessed: 18 October 2023). Notes to editors: Research Methodology The Clinician of the Future 2023: Education Edition presents the results of a global survey of 2,212 students and two roundtable sessions with key opinion leaders in faculty in the US and UK. The aim is to gain a deep understanding of students’ experiences today and their expectations of the future in healthcare, as well as the perspectives of those instructing them. Elsevier Health’s commitments In addition to the Clinician of the Future 2023: Education Edition, we are committed to the following: Community Advisor Programmes of Osmosis: Providing elements of mentorship and connection to clinician communities Campus visits and feedback from students: Listening and learning through student feedback on how they are approaching their education challenges Year of the Zebra: An initiative to increase awareness of rare diseases and the benefits of patient care Hackathons: Providing clinical challenges for students in North America to advance their clinical education. Hosting webinars on resilience and depression in healthcare, as well as developing podcast episodes relevant to healthcare challenges Continued internships for medical and nursing students Supporting scholarships for minority students through the Elsevier Foundation About Elsevier Health For more than 140 years, Elsevier has supported the work of researchers and healthcare professionals by providing current, evidence-based information, that can help empower students and clinicians to provide the best healthcare possible. Growing from our roots, Elsevier Health applies innovation, facilitates insights, and helps drive more informed decision-making for our customers across global health. We support health providers by providing accessible, trusted evidence-based information to take on the infodemic; prepare more future health professionals with effective tools and resources; provide insights that help clinicians improve patient outcomes; deliver healthcare that is truly inclusive; and supports a more personalized and localized healthcare experience. Diversity and inclusion are the foundation of our innovation, and our teams are committed to creating education and practice solutions that reflect the diversity of our world. Elsevier is helping lay the groundwork for more equitable healthcare worldwide; We bring the same rigor to our digital information solutions as we do to our publishing, allowing us to offer knowledge and valuable analytics that help our users make breakthroughs and drive progress for the benefit of every patient. About Elsevier As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, academic leaders, funders, R&D-intensive corporations, doctors, and nurses. Elsevier employs 9,000 people worldwide, including over 2,500 technologists. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, and health education. Researchers and healthcare professionals rely on over 2,800 journals, including The Lancet and Cell; 46,000+ eBook titles; and iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. Contact Details Dan DiPietro-James Global Media Relations Director dan.james@elsevier.com Chris West Senior Manager, Global Communications c.west1@elsevier.com Company Website https://www.elsevier.com/

October 30, 2023 03:45 AM Eastern Daylight Time

1 ... 5051525354 ... 206